Answer
Gefitinib targets cancers driven by activating EGFR mutations. Reliable tumour testing—and sometimes validated plasma ctDNA testing—is needed because mutation-negative tumours have not shown clinically relevant activity.
Sources for this answer
- Gefitinib Sandoz 250 mg Film-coated Tablets — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.